DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
” - 2 Katherine Tuttle - 2 Martin Holst Lange - 2 Ozempic - 1 Novo - 1 Subramaniam Pennathur - 1 Vlado Perkovic - 1 “ Semaglutide - 1
Top related locs:
United States Stockholm The University of New South Danish American
Top related orgs:
of Medicine - 2 Novo Nordisk - 2 Diabetes - 2 University of Washington School of Medicine - 1 Renal Association - 1 The New England - 1 and Drug Administration - 1 Michigan Medicine - 1

Search resuls for: "Katherine Tuttle"


2 mentions found


☆ Ozempic Cuts Risk of Chronic Kidney Disease Complications, Study Finds
  + stars: | 2024-05-24 | by ( Dani Blum | ) www.nytimes.com   time to read: +1 min
Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic kidney disease in a major clinical trial, the results of which were published on Friday. The findings could transform how doctors treat some of the sickest patients with chronic kidney disease, which affects more than one in seven adults in the United States but has no cure. The trial, funded by Ozempic maker Novo Nordisk, was so successful that the company stopped it early. Dr. Martin Holst Lange, Novo Nordisk’s executive vice president of development, said that the company would ask the Food and Drug Administration to update Ozempic’s label to say it can also be used to reduce the progression of chronic kidney disease or complications in people with Type 2 diabetes. Diabetes is a leading cause of chronic kidney disease, which occurs when the kidneys don’t function as well as they should.
Persons: Ozempic, ”, Katherine Tuttle, Martin Holst Lange, Novo, Subramaniam Pennathur Organizations: University of Washington School of Medicine, Renal Association, The New England, of Medicine, Novo Nordisk, and Drug Administration, Diabetes, Michigan Medicine Locations: United States, Stockholm, The
☆ Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds
  + stars: | 2024-05-24 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +8 min
Diabetes is a key risk factor for kidney disease, which is one of the leading causes of death in the United States and worldwide; about 1 in 3 people with diabetes also has chronic kidney disease, according to the US Centers for Disease Control and Prevention. But new research shows that weekly injections of semaglutide cut the risk of severe outcomes from diabetic kidney disease by about 24%. The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. “Kidney disease attributed to diabetes, or diabetic kidney disease, is one of the most common and deadly complications of diabetes. Yet, unfortunately, there’s very low awareness around it,” said Dr. Katherine Tuttle, chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology.
Persons: ”, Vlado Perkovic, “ Semaglutide, Martin Holst Lange, Katherine Tuttle, ” It’s, Tuttle, semaglutide, It’s, Dr, Sanjay Gupta, White, ” Tuttle Organizations: CNN, Diabetes, US Centers for Disease Control, New England, of Medicine, European Renal Association Congress, University of New, University of New South Wales Sydney, Novo Nordisk, American Society of Nephrology, Providence Inland Northwest Health, Health Sciences, University of Washington, CNN Health Locations: United States, University of New South, Danish, American
0 next >>
Total: 2